Anthracyclines are commonly used for treating multiple myeloma (MM) and have been incorporated into a number of well-established regimens.1–3 The major mechanisms for resistance to daunorubicin in the treatment of MM include amplification or overexpression of the multidrug resistance 1 (MDR-1) gene, which codes for transmembrane P-glycoprotein (PGP). Here, PGP is linked to Miyoshi myopathy.